Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | KIF11 | P52732 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.42 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.42 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2975736 | 0.83 | KIF11 (0.48) | KIF11MAPTCA12CA9MAPK1 | |
| SCHEMBL13384023 | 0.80 | PTGS1 (0.54) | PTGS1PTGS2KIF11MAPTMITF | |
| SCHEMBL2972598 | 0.77 | TUBB1 (0.70) | PTGS1PTGS2MAPTMITFTUBB1 | |
| SCHEMBL2980199 | 0.76 | MAP2K4 (0.55) | KIF11MAPTMAPK1MAP2K4MAPK6 | |
| SCHEMBL2971584 | 0.75 | MAPT (0.59) | PTGS1PTGS2MAPTMITFMAPK1 | |
| SCHEMBL2981080 | 0.75 | ALDH1A1 (0.53) | PTGS1PTGS2KIF11MAPTMITF | |
| SCHEMBL9776264 | 0.74 | SRD5A2 (0.68) | — | |
| SCHEMBL2977493 | 0.73 | MEN1 (0.51) | PTGS1PTGS2TUBB1 | |
| SCHEMBL13772408 | 0.73 | KIF11 (0.84) | KIF11MAPT | |
| SCHEMBL13581347 | 0.72 | PTGS1 (0.65) | PTGS1PTGS2KIF11MAPTTUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1837329-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286144-A1 | HETEROARYL DERIVATIVES | GPR119, SLC2A1, SLC2A4 | PTGS1 3116/4885PTGS2 2919/4885KIF11 4704/4885 |
| US-20080167306-A1 | Novel Heteroaryl Derivative | GPR119, SLC2A4, SLC5A2 | PTGS1 3436/4885PTGS2 3183/4885KIF11 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.